Literature DB >> 9707619

Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting.

S Malkhosyan1, J Yasuda, J L Soto, T Sekiya, J Yokota, M Perucho.   

Abstract

Genomic instability characterizes the aneuploid cancer cell. Losses of genetic material are critical in cancer by exposing recessive mutations in tumor suppressor genes. Gains of genetic material also may lead to overexpression of genes contributing to tumor progression either in the presence or absence of mutation. However, the detection of moderate gains (such as tri-tetraploidy) has been a challenge in cancer research. Unbiased DNA fingerprinting by the arbitrarily primed PCR allows the detection of moderate gains (in addition to losses) of DNA sequences of known chromosomal localization. We have generated in this manner a molecular karyotype of metastatic colon cancer. This amplotype shows that sequences from several chromosomes undergo both losses (1, 4, 9, 14, and 18) and gains (6, 7, 12, and 20) in over half of the tumors. Moreover, gains of sequences from chromosomes 8 and 13 occurred in most tumors, indicating the existence in these chromosomes of positive regulators of cell growth or survival that are under strong positive selection during tumor progression. We conclude that overrepresentation of these chromosomal regions is a critical step for metastatic colorectal cancer. Comparative amplotype analysis from primary and metastatic tumors suggest the existence in chromosome 4 of gene(s) whose loss is specifically selected in cells that reach the metastatic stage.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9707619      PMCID: PMC21480          DOI: 10.1073/pnas.95.17.10170

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin.

Authors:  C Shih; B Z Shilo; M P Goldfarb; A Dannenberg; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

2.  Variable number of tandem repeat (VNTR) markers for human gene mapping.

Authors:  Y Nakamura; M Leppert; P O'Connell; R Wolff; T Holm; M Culver; C Martin; E Fujimoto; M Hoff; E Kumlin
Journal:  Science       Date:  1987-03-27       Impact factor: 47.728

3.  Control of the reversion of properties in transformed cells.

Authors:  Z Rabinowitz; L Sachs
Journal:  Nature       Date:  1970-01-10       Impact factor: 49.962

4.  Expression of recessive alleles by chromosomal mechanisms in retinoblastoma.

Authors:  W K Cavenee; T P Dryja; R A Phillips; W F Benedict; R Godbout; B L Gallie; A L Murphree; L C Strong; R L White
Journal:  Nature       Date:  1983 Oct 27-Nov 2       Impact factor: 49.962

5.  Triplication of one chromosome No. 15 with an altered c-myc containing EcoRI fragment and elimination of the normal homologue in a T-cell lymphoma line of AKR origin (TIKAUT).

Authors:  Z Wirschubsky; F Wiener; J Spira; J Sümegi; G Klein
Journal:  Int J Cancer       Date:  1984-04-15       Impact factor: 7.396

6.  Allelotype of colorectal carcinomas.

Authors:  B Vogelstein; E R Fearon; S E Kern; S R Hamilton; A C Preisinger; Y Nakamura; R White
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

7.  Oncogene amplification during tumorigenesis of established rat fibroblasts reversibly transformed by activated human ras oncogenes.

Authors:  E Winter; M Perucho
Journal:  Mol Cell Biol       Date:  1986-07       Impact factor: 4.272

8.  A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells.

Authors:  E Winter; F Yamamoto; C Almoguera; M Perucho
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

9.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

10.  Detection of somatic changes in human cancer DNA by DNA fingerprint analysis.

Authors:  S L Thein; A J Jeffreys; H C Gooi; F Cotter; J Flint; N T O'Connor; D J Weatherall; J S Wainscoat
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

View more
  8 in total

1.  How many mutations does it take to make a tumor?

Authors:  C R Boland; L Ricciardiello
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Genetics and pathology of pancreatic cancer.

Authors:  Jordan M Winter; Anirban Maitra; Charles J Yeo
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

3.  Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice.

Authors:  Meredith A Collins; Filip Bednar; Yaqing Zhang; Jean-Christophe Brisset; Stefanie Galbán; Craig J Galbán; Sabita Rakshit; Karen S Flannagan; N Volkan Adsay; Marina Pasca di Magliano
Journal:  J Clin Invest       Date:  2012-01-09       Impact factor: 14.808

Review 4.  DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer.

Authors:  Johanna K Samuelsson; Sergio Alonso; Fumiichiro Yamamoto; Manuel Perucho
Journal:  Mutat Res       Date:  2010-09-17       Impact factor: 2.433

5.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

6.  DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free.

Authors:  Ru Chen; Peter S Rabinovitch; David A Crispin; Mary J Emond; Kent M Koprowicz; Mary P Bronner; Teresa A Brentnall
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

7.  Methylation and expression of the tumour suppressor, PRDM5, in colorectal cancer and polyp subgroups.

Authors:  Catherine E Bond; Mark L Bettington; Sally-Ann Pearson; Diane M McKeone; Barbara A Leggett; Vicki L J Whitehall
Journal:  BMC Cancer       Date:  2015-01-23       Impact factor: 4.430

8.  SLC4A2 anion exchanger promotes tumour cell malignancy via enhancing net acid efflux across golgi membranes.

Authors:  Elham Khosrowabadi; Antti Rivinoja; Maija Risteli; Anne Tuomisto; Tuula Salo; Markus J Mäkinen; Sakari Kellokumpu
Journal:  Cell Mol Life Sci       Date:  2021-07-19       Impact factor: 9.261

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.